Acelyrin Sees Stock Price Rise Amid Rights Plan
Fewer, But Larger, Local Bioscience Funding Deals
Acelyrin Buys Maryland Immunotherapy Firm
Execs Hired At Acelyrin
Acelyrin Raises $300M to Further Growth
Valley 200 2026: Jarred Walker
Valley 200 2026: Shep Wainwright
Valley 200 2026: Craig Strong
Valley 200 2026: David “Randy” Stevenson
Valley 200 2026: George Stavaris